**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 54742

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure**

Bahrehbar K *et al.* Stem cells for premature ovarian failure

Khadijeh Bahrehbar, Mojtaba Rezazadeh Valojerdi, Fereshteh Esfandiari, Rouhollah Fathi, Seyedeh-Nafiseh Hassani, Hossein Baharvand

**Khadijeh Bahrehbar, Fereshteh** **Esfandiari, Seyedeh-Nafiseh Hassani, Hossein Baharvand,** Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran 1665659911, Iran

**Khadijeh Bahrehbar, Hossein** **Baharvand,** Department of Developmental Biology, University of Science and Culture, Tehran 1665659911, Iran

**Mojtaba** **Rezazadeh Valojerdi, Rouhollah Fathi,** Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, Tehran 1665659911, Iran

**Mojtaba Rezazadeh Valojerdi,** Department of Anatomy, Faculty of Medical Science, Tarbiat Modares University, Tehran 1665659911, Iran

**Author contributions:** Bahrehbar K and Esfandiari F were involved in collection and/or assembly of the data and manuscript writing; Bahrehbar K, Rezazadeh Valojerdi M, Baharvand H, Fathi R and Hassani SN were involved in data analysis and interpretation; Esfandiari F, Fathi R and Hassani SN were involved in conception and design; Rezazadeh Valojerdi M and Baharvand H were co-corresponding authors and were involved in conducting the experiments, manuscript proof, administrative and financial support.

**Supported by** Royan Institute, the National Institute for Medical Research Development, No. 963255; and the Ministry of Health and Medical Education, No. 700/147.

**Corresponding author: Hossein Baharvand, PhD, Full Professor,** Department of Stem Cells and Developmental Biology, Royan Institute for Stem Cell Biology and Technology, Banihashem St., Tehran 1665659911, Iran. [baharvand@royaninstitute.org](mailto:baharvand@royaninstitute.org)

**Received:** February 22, 2020

**Revised:** June 1, 2020

**Accepted:** July 18, 2020

**Published online:** August 26, 2020

**Abstract**

BACKGROUND

Premature ovarian failure (POF) affects many adult women less than 40 years of age and leads to infertility. According to previous reports, various tissue-specific stem cells can restore ovarian function and folliculogenesis in mice with chemotherapy-induced POF. Human embryonic stem cells (ES) provide an alternative source for mesenchymal stem cells (MSCs) because of their similarities in phenotype and immunomodulatory and anti-inflammatory characteristics. Embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) are attractive candidates for regenerative medicine because of their high proliferation and lack of barriers for harvesting tissue-specific MSCs. However, possible therapeutic effects and underlying mechanisms of transplanted ES-MSCs on cyclophosphamide and busulfan-induced mouse ovarian damage have not been evaluated.

AIM

To evaluate ES-MSCs *versus* bone marrow-derived mesenchymal stem cells (BM-MSCs) in restoring ovarian function in a mouse model of chemotherapy-induced premature ovarian failure.

METHODS

Female mice received intraperitoneal injections of different doses of cyclophosphamide and busulfan to induce POF. Either human ES-MSCs or BM-MSCs were transplanted into these mice. Ten days after the mice were injected with cyclophosphamide and busulfan and 4 wk after transplantation of the ES-MSCs and/or BM-MSCs, we evaluated body weight, estrous cyclicity, follicle-stimulating hormone and estradiol hormone concentrations and follicle count were used to evaluate the POF model and cell transplantation. Moreover, terminal deoxynucleotidyl transferase mediated 2-deoxyuridine 5-triphosphate nick end labeling, real-time PCR, Western blot analysis and immunohistochemistry and mating was used to evaluate cell transplantation. Enzyme-linked immunosorbent assay was used to analyze vascular endothelial growth factor, insulin-like growth factor 2 and hepatocyte growth factor levels in ES-MSC condition medium in order to investigate the mechanisms that underlie their function.

RESULTS

The human ES-MSCs significantly restored hormone secretion, survival rate and reproductive function in POF mice, which was similar to the results obtained with BM-MSCs. Gene expression analysis and the terminal deoxynucleotidyl transferase mediated 2-deoxyuridine 5-triphosphate nick end labeling assay results indicated that the ES-MSCs and/or BM-MSCs reduced apoptosis in the follicles. Notably, the transplanted mice generated new offspring. The results of different analyses showed increases in antiapoptotic and trophic proteins and genes.

CONCLUSION

These results suggested that transplantation of human ES-MSCs were similar to BM-MSCs in that they could restore the structure of the injured ovarian tissue and its function in chemotherapy-induced damaged POF mice and rescue fertility. The possible mechanisms of human ES-MSC were related to promotion of follicular development, ovarian secretion, fertility *via* a paracrine effect and ovarian cell survival.

**Key words:** Premature ovarian failure; Human embryonic stem cells; Chemotherapy drugs; Mesenchymal stem cell; Bone marrow; Apoptosis

Bahrehbar K, Rezazadeh Valojerdi M, Esfandiari F, Fathi R, Hassani SN, Baharvand H.Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure. *World J Stem Cells* 2020; 12(8): 857-878 URL: https://www.wjgnet.com/1948-0210/full/v12/i8/857.htm DOI: https://dx.doi.org/10.4252/wjsc.v12.i8.857

**Core tip:** Transplanted human embryonic stem cells are similar to bone marrow-derived mesenchymal stem cells. They can restore injured ovarian tissue structure and function in chemotherapy-induced premature ovarian failure mice and rescue fertility through the paracrine effect and ovarian cell survival.

**INTRODUCTION**

Premature ovarian failure (POF) disease has similar characteristics such as hypoestrogenism, elevated gonadotropin levels and infertility in animal models and in human. Some women also have symptoms such as hot flashes, night sweats, vaginal dryness, chronic anxiety, sadness and depression[1]. POF affects 1%-3% of women < 40 years of age[2]. Hot flashes, depression, anxiety, osteoporosis and sexual dysfunction are the consequences of this disease[3,4]. Although the cause of POF is often idiopathic, possible causes include autoimmune disorders, smoking, toxic chemicals, drugs and genetic defects[5-7]. Chemotherapeutics such as cyclophosphamide (Cy) and busulfan (Bu) are the most gonadotoxic agents that lead to POF in the majority of patients[8]. Currently, ovarian protection methods, oocyte or ovarian tissue cryopreservation and embryo freezing are strategies used for fertility preservation in women diagnosed with cancer. However, these methods have serious disadvantages such as the risk of reintroducing the cancer cells, delays in cancer treatment and low success rate. Therefore, it is necessary to develop advanced therapies for women with POF[9].

Emerging evidence suggests that mesenchymal stem cells (MSCs) derived from bone marrow (BM) and other adult tissues (adipose, skin, amniotic membrane, placenta) and menstrual blood could restore ovarian function in animal models of POF[10-14]. A meta-analysis from 16 preclinical studies of animal models was conducted to assess the efficacy of stem cell transplantation. The results indicated that MSC therapy significantly improved ovarian function in cases with POF[15]. In two case studies, MSC transplantation also improved POF[15-16]. However, despite the promising results, the numbers of harvested MSCs and their *in vitro* expansion was a challenge[17]. Moreover, obtaining MSCs from bone marrow requires suitable donors and invasive procedures. The number of bone marrow-derived mesenchymal stem cells (BM-MSCs) is very limited, which greatly restricts use of BM-MSCs for clinical application[18]. The immunomodulating feature of MSCs seems to be different between species[19]. Human MSCs decrease the secretion of interferon gamma, interleukin 12 and tumor necrosis factor alpha and increase interleukin 10 secretion[20-22]. Moreover, human MSC-mediated inhibition of the T cell response could not be reversed by nitric oxide synthase inhibitor compared with mice MSCs[23]. Integrin β1 expression is important for mice MSCs migration, while C-X-C chemokine receptor type 4 expression is involved for human MSC migration to sites of tissue injury[24-25]. It has been demonstrated that 92% of MSC protein expression is similar in humans and mice [26]. MSCs represent only a small proportion of the cells in bone marrow, and their proliferation and differentiation capacity correlates inversely with age[20].

In addition to adult tissue specific MSCs, human embryonic stem cells (ES-MSCs) are an alternative source of MSCs because of their similar phenotypic characteristics that make them attractive candidates for regenerative cellular therapy[27-28]. Recently, it has been reported that ES-MSCs have higher capabilities for cell proliferation and suppression of leukocyte growth compared to MSCs from other sources[29-30]. ES-MSCs exhibited more potent anti-inflammatory properties than BM-MSCs[17,27,31-33]. The therapeutic potential of ES-MSCs has been reported in numerous animal models. When compared with BM-MSCs, these cells showed a significantly greater improvement in models of thioacetamide-induced chronic liver injury and experimental autoimmune encephalitis[30,34]. This evidence indicates that ES-MSCs may serve as better sources for clinical applications.

Human ES-MSCs can overcome the obstacles seen with harvesting MSCs from adult tissues, including lack of appropriate donors, limited numbers of cells obtained during the harvesting process, restricted *in vitro* expansion capacity and the invasiveness of the procedures. Thus, we hypothesized that ES-MSCs might restore ovarian structure and function through the paracrine mechanisms of cytokines in a POF model. To address this issue, we used a POF mouse model to evaluate the potential for transplanted ES-MSCs to restore fertility.

**MATERIALS AND METHODS**

***Derivation of MSCs from human ES cells and BM***

We isolated and cultured ES-MSCs according to our previously published protocols[17,33]. Briefly, we obtained MSCs from human ES cells by culturing these cells in basic fibroblast growth factor-free ES medium to enable embryoid body formation. The resultant embryoid bodies were plated in gelatin-coated plates and cultured in MSC medium. Spontaneous differentiation of the embryoid bodies resulted in an outgrowth of ES-MSCs. These cells were further passaged to obtain a homogenous population with spindle-shaped morphology. Passage-2 human BM-MSCs were prepared from Royan Stem Cell Bank (Tehran, Iran) and cultured in low-glucose Dulbecco’s Modified Eagle Medium (Life Technologies, United States) supplemented with 10% fetal bovine serum (FBS, Life Technologies, United States) for further expansion. The medium was changed every 3 d.

***Cell proliferation analysis***

We cultured 1 × 106 cells/cm2 in T25 cm2 tissue culture flasks (TPP, Germany) to assess their proliferative ability. The population doubling time was calculated according to the following formula:

population doubling time = duration × log (2)/log (final concentration) – log (initial concentration)

Karyotype analysis

The cells were treated with 0.66 mmol/L thymidine (Sigma-Aldrich) and incubated at 37 °C for 16 h. After the cells were washed with phosphate buffered saline (PBS), they were left for 5 h and then treated with 0.15 mg/mL colcemid (Invitrogen) for 30 min. Then, the cells were exposed to 0.075 mol/L potassium chloride (Merck) and allowed to incubate at 37 °C for 16 min. After the cells were centrifuged, we removed the supernatant and resuspended the pellet in Carnoy's fixative (3:1 ratio of methanol:glacial acetic acid). The cells were dropped onto precleaned, chilled slides and standard G-band staining was performed for chromosome visualization. We screened at least 20 well-spread metaphase cells of which 10 were evaluated for chromosomal rearrangements.

***Flow cytometry analysis***

We sought to determine the immunophenotypes of the cultured ES-MSCs and BM-MSCs. Surface-marker expression was analyzed by flow cytometry using the following antibodies: Fluorescein isothiocyanate-conjugated human monoclonal antibodies against protein tyrosine phosphatase receptor type C and cluster of differentiation (CD) 90 (CD90); and phycoerythrin-conjugated human monoclonal antibodies against homing cell adhesion molecule, CD73, endoglin, CD11b and CD34. For flow cytometric analysis, the adherent cells were detached by using 0.25% trypsin-ethylenediaminetetraacetic acid, neutralized by FBS-containing culture medium and disaggregated into single cells by pipetting. The cells were incubated with antibodies for 30 min at 4 °C, washed twice with PBS, resuspended in 0.5 ml PBS and immediately analyzed by fluorescence-activated cell sorting Calibur flow cytometer (Becton Dickinson, United States). Analyses were performed on three independent biological samples. Data were analyzed using the FlowJo software (version 7.6.1). Supplementary Table 1 lists the antibodies used in this study.

***Multilineage differentiation***

Osteogenic, adipogenic and chondrogenic differentiation were verified by alizarin red, oil red O, and alcian blue staining, respectively to confirm the multipotent properties of the ES-MSCs and BM-MSCs. For osteogenesis, the cells were seeded onto 6-well plates at a density of 1 × 105 cells/cm2. After 24 h, the medium was replaced by osteogenic differentiation medium, alpha minimum essential medium (Life Technologies, United States) supplemented with 10% FBS (Gibco, United States), 0.1 mmol/L dexamethasone (Sigma-Aldrich, United States), 10 mmol/L β-glycerophosphate (Sigma-Aldrich, United States) and 50 mmol/L ascorbic acid (Sigma-Aldrich, United States) for 2 wk. To induce adipogenesis, the cells were incubated with adipogenic differentiation medium in alpha minimum essential medium supplemented with 10% FBS, 10 mg/mL insulin (Sigma-Aldrich, United States), 1 mmol/L dexamethasone (Sigma-Aldrich, United States), 0.5 mmol/L isobutyl-methylxanthine (Sigma-Aldrich, United States) and 100 mmol/L indomethacin (Sigma-Aldrich, United States) for 3 wk. For chondrogenic differentiation, 2.5 × 105 cells were collected in a 15 mL tube and centrifuged at 350 g for 5 min. The cell pellet was subsequently cultured for 3 wk using chondrogenic induction medium (chondrogenesis differentiation kit, Gibco, United States) according to the manufacturer’s instructions. Then, the pellets were fixed in 4% paraformaldehyde (Sigma Aldrich, United States) for 30 min, dehydrated in ethanol, cleared in xylene and embedded in paraffin. The paraffin-embedded cells were sectioned into 6 µm sections by using a microtome. The sections were stained with alcian blue.

***Measurement of cytokine secretion***

We analyzed cytokines secreted by the MSCs. Both ES-MSCs and BM-MSCs were cultured in dishes at densities of 2 × 105 cells/cm2 each. After a 24 h culture in serum-free media, the culture media was collected and centrifuged at 2000 *g* for 5 min. The amount of cytokine expression was measured using a vascular endothelial growth factor (VEGF) Human ELISA kit (Invitrogen, United States), insulin-like growth factor 2 (IGF-2) Human ELISA kit (R&D Systems, United States) and hepatocyte growth factor (HGF) Human ELISA kit (R&D Systems, United States).

***Experimental animals***

All animal experiments were approved by the Institutional Ethical Committee of Royan Institute. Adult female C57BL/6 mice (6-8 wk old) were used in our study. The mice were housed under a 14-10 h light-dark cycle and had free access to food and water.

***Estrous cyclicity***

Vaginal smears were obtained daily. The four stages of the estrous cycle were determined as follows: Proestrus (100% intact live epithelial cells); estrus (100% cornified epithelial cells); metestrus (about 50% cornified epithelial cells and about 50% leukocytes); and diestrus (80%-100% leukocytes). The mouse estrous cycle lasts for approximately 4 d and includes the proestrus, estrus, metestrus and diestrus stages. Animals with at least two consecutive normal 4-d vaginal estrous cycles were included in the experiments. In order to validate reproductive function, we assessed the animals over 10 consecutive days of the experiment. The number of estrous cycles were checked at 8:00 am daily with a vaginal smear assay starting at 10 d after the animals were injected with Cy and Bu and 4 wk after transplantation of ES-MSCs or BM-MSCs.

***Establishment of the POF model***

In this study, we used chemotherapy to create the mouse model because chemotherapy is one of the major causes of POF[35]. Various reports of POF models generated in mice used from 8-30 mg/kg of Bu plus 50-200 mg/kg of Cy[36-40]. or only Cy[41-44]. However, none of the previous studies showed any significant decrease in follicle numbers during the developmental stages. Therefore, we assessed different doses of these drugs to create a POF model in our laboratory setting. Female mice were randomly divided into four treatment groups and one intact group. The treatment groups received intraperitoneal injections of different doses of Cy (Endoxan™, Germany) and Bu (Sigma-Aldrich, United States) as follows: Group 1 (POF1): 50 mg/kg Bu and 100 mg/kg Cy; group 2 (POF2): 100 mg/kg Cy for 10 consecutive days; group 3 (POF3): 200 mg/kg Cy and 50 mg/kg Bu on the 1st day followed by 50 mg/kg Cy and 5 mg/kg Bu for 9 consecutive days; and group 4 (POF4): A single injection of 20 mg/kg Bu and 200 mg/kg Cy. In order to confirm successful establishment of POF in the mouse model, we checked their body weights, estrous cyclicity, concentrations of follicle-stimulating hormone (FSH) and estradiol (E2) hormones and follicle counts. In addition, for further confirmation of POF, we also used the terminal deoxynucleotidyl transferase mediated 2-deoxyuridine 5-triphosphate nick end labeling (TUNEL) assay and real-time PCR assessments, and the mice were allowed to mate 10 d after the injections.

***Cell transplantation***

Once the POF model was established, we randomly divided the mice into three groups. Vehicle POF mice received medium but no cell transplantation. In the ES-MSC group, POF mice were injected with 1 × 106 ES-MSCs. In the BM-MSC group, POF mice were injected intravenously with 1 × 106 BM-MSCs in 0.1 mL Dulbecco’s Modified Eagle Medium. In order to evaluate the effects of the transplanted ES-MSCs and BM-MSCs, we assessed the body weights, estrous cyclicity, concentrations of FSH and E2 hormones and follicle counts in the POF mice at 4 wk after the transplantations. In addition, the mice were allowed to mate. The TUNEL assay, Western blot, immunohistochemistry and real-time PCR assessments were also performed.

***Hormone assay***

Blood samples were obtained from hearts of the anesthetized mice to determine serum levels of E2 and FSH. The blood samples were incubated at room temperature for 1 h, and supernatant was collected after centrifugation at 3000 rpm for 20 min. Hormone levels were determined by ELISA kits (Biotech, Shanghai, China).

***Detection of apoptosis by the TUNEL assay***

Cell apoptosis in the ovarian tissue was detected by the TUNEL assay. Briefly, 5 μm ovarian sections were washed twice in PBS for 5 min after deparaffinization. These sections were permeabilized by incubation in 0.1% Triton X-100 solution and 0.1% sodium citrate for 8 min. Then, the TUNEL assay was performed with an *in situ* cell death detection kit (Roche, Germany) according to the manufacturer’s instructions. Counterstaining with DAPI (Sigma-Aldrich) was used to visualize the nuclei. We observed the cells under a fluorescence microscope (Olympus, Japan) for the presence of apoptosis (green fluorescent color).

***Hematoxylin and eosin staining and data quantification***

The ovaries were removed and fixed in 4% paraformaldehyde (Sigma-Aldrich) for at least 24 h. The fixed ovaries were dehydrated, embedded in paraffin, serially sectioned into 6 μm sections and mounted on glass microscope slides. Routine hematoxylin and eosin staining was performed for histologic examination under a light microscope.

***Follicle counting***

Primordial, primary, secondary and antral follicles were counted in each of the five sections based on the method reported by Tilly[45]. Only the follicle with a nucleus was counted to avoid duplicate counting of a follicle. The follicles were classified as: Primordial (oocyte surrounded by a single layer of squamous granulosa cells); primary (intact enlarged oocyte with a visible nucleus and one layer of cuboidal granulosa cells); secondary (two or three layers of cuboidal granulosa cells without an antral space); early antral (emerging antral spaces); and preovulatory (the largest follicular types with a defined cumulus granulosa cell layer). Supplementary Tables 3 and 4 present the data for follicle counting both after chemotherapy and cell transplantation. The significance of the changes in follicle numbers in the different study groups were analyzed by two-way analysis of variance.

***Gene expression analysis***

Quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) was performed for the apoptosis genes, anti-apoptosis gene [B-cell lymphoma 2 (*Bcl2*)], apoptosis gene [cysteine-aspartic proteases 3 (*caspase 3*)], angiogenesis gene (*Vegf*), proliferation gene (*Igf*-*2*), granulosa marker anti-Müllerian hormone (*Amh*)] and oocyte marker [growth/differentiation factor 9 (*Gdf9*)] in the intact group, POF group and both cell transplantation groups. Total RNA was isolated and purified with TRIzol reagent (Invitrogen) according to the manufacturer’s protocol followed by cDNA synthesis with a cDNA synthesis kit (Fermentas). qRT-PCR reactions were performed using SYBR Green Master Mix (Applied Biosystems) and a real-time PCR system (Corbett Life Science; Rotor-Gene 6000 instrument). The samples were collected from three independent biological replicates. Supplementary Table 2 lists the primer sequences used for qRT-PCR.

***Western blot analysis***

The protein expression of caspase 3 in the ovaries was measured by Western blot. The mice were anesthetized, and we removed their ovaries. The proteins from the ovaries were isolated by the Q Proteome Mammalian Protein Prep kit (Merck, Germany). The total protein concentrations were measured using a standard BCA protein assay kit. The protein from each group was separated on 12% SDS-PAGE and transferred onto PVDF membranes. The blots were then incubated in blocking buffer [2% (w/v) skim milk powder in TBST] for 1 h at room temperature. Then, the membranes were incubated overnight at 4 °C with the primary antibody, anti-caspase 3 (1:2000[46]). The membranes were washed three times with TBST and incubated at room temperature for 1 h with anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:1000).

***Immunohistochemistry***

Expression of the granulosa cell marker (Amh) was detected by immunohistochemical staining. The ovaries were fixed in formalin and sectioned into 5 μm sections. The sections were incubated at 60 °C for 1 h, deparaffinized in xylene and rehydrated in a graded ethanol series. Then, antigen retrieval was performed by heating the sections in citrate buffer in an oven for 30 min. The sections were washed in H2O2 for 30 min to eliminate endogenous peroxidase activity and blocked with goat serum for 1 h at room temperature. After that, the sections were incubated overnight at 4 °C with the primary antibody, anti-Amh. After three washes with PBS for 10 min each time, the secondary antibody, streptavidin, and DAB were used for immunostaining according to the protocol from an immunostaining kit (Merck, Germany). Finally, the sections were counterstained with hematoxylin, dehydrated and mounted.

***Mating trial***

The mating trial was initiated 10 d after the mice were injected with Cy or 4 wk after transplantation of the ES-MSCs or BM-MSCs and continued for six weeks. Female mice were housed in the same cages with male mice for natural mating. The presence of a copulatory plug indicated successful mating. Males were randomly rotated among the cages after each pregnancy and the numbers of offspring per litter were recorded.

***Statistical analysis***

All experiments were conducted in at least three independent repeats. All data are shown as mean ± standard error of the mean. One-way analysis of variance was used to determine significant differences among groups with Tukey’s post-hoc test. Viability was analyzed by the *t* test. *P* < 0.05 were considered significant.

**RESULTS**

***Derivation and characterization of ES-MSCs and BM-MSCs***

Figure 1A shows the procedure used to derive MSCs from the ES cells. MSCs derived from both human ES and BM formed a homogeneous cell population with spindle-shaped morphology and a normal karyotype during long-term culture (Figure 1B and 1C). The MSCs successfully differentiated into osteogenic, adipogenic and chondrogenic lineages (Figure 1D). Flow cytometry analysis confirmed the expression of MSC-specific markers homing cell adhesion molecule, CD73, CD90 and endoglin by both human ES-MSCs and BM-MSCs; there were no detectable levels of the hematopoietic and endothelial cell markers (CD11b, CD34 and protein tyrosine phosphatase receptor type C) (Figure 1E and 1F, Supplementary Figure 1). The population doubling time assay showed significant increases in ES-MSC proliferation compared to BM-MSCs (Figure 1G; *P* < 0.05).

***Establishment of a mouse model of chemotherapy-induced POF***

We examined various concentrations of four different combinations of two chemotherapy drugs, Cy and Bu, in order to establish a POF model that showed the significant decreases in follicle numbers for all of the developmental stages (Figure 2A). In the intact group, the mice had regular 4-d estrous cycles; however, irregular estrous cycles were observed in the POF1, POF2, POF3 and POF4 mice. On day 5 of the treatment, the POF1, POF2 and POF3 mice were eating less and moved slowly (data not shown). The ovaries of the mice in the intact group were more reddish in color, whereas the ovaries of the mice that survived in the POF groups were pale. All of the animals were weighed before and after modeling, and we found significantly reduced body weights in the POF1 and POF2 groups (Figure 2B, Supplementary Figure 2A; *P* < 0.05). Furthermore, the size of ovaries in mice treated with the chemotherapy drugs in the POF1, POF2, POF3 and POF4 groups were smaller than ovaries from the intact mice (Supplementary Figure 2B).

We performed hematoxylin and eosin staining to evaluate the structures of the ovaries following chemotherapy. Quantification of the follicles showed significant decreases in all of the developmental stages in the POF1 and POF2 groups (Figure 2C; Supplementary Figure 3; *P* < 0.05), while the POF3 and POF4 groups did not show significant decreases in the number of follicles in the various developmental stages.

Hormonal analysis demonstrated significant increases in serum levels of FSH and significant decreases in E2 levels in the POF1 and POF2 groups (Figure 2D and 2E; *P* < 0.05). TUNEL assay results to evaluate apoptosis in the ovaries following chemotherapy (Supplementary Figure 4A) showed a significantly increased percentage of TUNEL-positive cells in the POF1 and POF2 groups compared to the intact group (Figure 2F; *P* < 0.05). Next, we sought to determine the optimum POF model by evaluating the survival rate of the mice and the pregnancy rate following chemotherapy. We found significantly higher survival rates in the POF1 group compared to the POF2 group (Figure 2G; *P* < 0.01). However, none of the POF mice became pregnant (Supplementary Figure 4B). Therefore, we selected the POF2 model as the most appropriate model for induction of POF.

***ES-MSCs and BM-MSCs improved the POF model***

We explored the possibility that the MSCs could improve the POF mouse model. There were more regular estrous cycles following transplantation of both human ES-MSCs and BM-MSCs compared to the vehicle group. Moreover, the ovaries of the mice had an increased red color and were larger in size following transplantation of both ES-MSCs and BM-MSCs in comparison with the vehicle group, but they were less than the intact ovaries (Supplementary Figure 5). Body weight significantly increased 4 wk after transplantation of both ES-MSCs and/or BM-MSCs compared to the vehicle group (Figure 3A; *P* < 0.05). The survival rate significantly increased following transplantation of ES-MSCs and/or BM-MSCs (more than 60%) compared to the vehicle group (20%) (Figure 3B; *P* < 0.01).

Notably, we observed significant increases in the number of follicles at all stages of development following transplantation of both ES-MSCs and BM-MSCs compared with the vehicle group (Figure 3C; *P* < 0.05). Transplantation of both ES-MSCs and BM-MSCs significantly decreased the FSH levels and increased the E2 levels compared with the vehicle group (Figure 3D and 3E; *P* < 0.05).

The results of the TUNEL assay confirmed significant decreases in apoptosis in ovaries that received the cell transplantations (Figure 4A and 4B, Supplementary Figure 6; *P* < 0.05). qRT-PCR was conducted in order to gain further insight into the effect of transplantation on the ovaries. The results showed significant downregulation of the apoptosis gene, *caspase 3,* while the anti-apoptotic gene, *Bcl2,* was significantly upregulated following cell transplantation compared with the vehicle group. In particular, the level of the angiogenesis gene (*Vegf*), proliferation gene *(Igf-2)* and granulosa marker *(Amh)* significantly increased following cell transplantation. In contrast, we observed no significant differences in the oocyte marker, *Gdf9,* following transplantation (Figure 4C; *P* < 0.05).

Cleaved- caspase 3 acts as a functional enzyme[47,48].; therefore, to further validate these results, we performed Western blot assessment of cleaved-caspase 3 protein expression. Our results showed a significant increase in the cleaved-caspase 3 protein expression level in ovaries from the vehicle group compared with the control group, whereas the cleaved-caspase 3 protein expression level decreased significantly in the ovaries after transplantation of ES-MSCs and/or BM-MSCs compared with the vehicle group (Figure 4D and 4E; *P* < 0.05 ). Previous studies suggested that MSCs secrete cytokines that are important for anti-apoptosis, angiogenesis, anti-inflammation, anti-fibrosis and immunoregulation, which would improve the microenvironment for promoting regeneration of injured tissues in numerous diseases[49-53]. In order to investigate the mechanism that underlies the function of these MSCs, we also analyzed VEGF, IGF-2 and HGF levels in ES-MSCs and BM-MSCs condition media by using ELISA. The results showed that in a similar manner ES-MSCs and BM-MSCs secreted VEGF, IGF-2 and HGF *in vitro* (Figure 4F). However, there were only a few GFP-labelled cells after 4 wk in the ovaries (data not shown).

Immunohistochemistry staining for Amh to confirm the changes in the granulosa cells showed decreased Amh expression in ovaries from the vehicle group compared to the intact group and increased Amh expression in ovaries from both the ES-MSCs and BM-MSCs transplantation groups compared with the vehicle group (Figure 5A).

We assessed the ability of mice that received the transplantations to conceive and give birth to offspring. The successful mating rate was investigated over 6 wk, and the presence of a copulatory plug indicated successful mating. The mice that received transplantations of both ES-MSCs (3 out of 5 mice) and/or BM-MSCs (2 out of 5 mice) became pregnant and produced live offspring, 9 pups in mice transplanted with BM-MSCs and 16 pups in mice that received ES-MSCs. None of the vehicle mice became pregnant. These results showed that ovarian functions in mice with POF were partially restored by transplantation with either ES-MSCs or BM-MSCs (Figure 5B and 5C; *P* < 0.05).

**DISCUSSION**

Understanding the pathogenesis of POF plays an important role in the development of effective therapeutic options for this disease. Therefore, elucidation of the mechanism for POF development is critical for the clinical treatment of POF disease[54]. The estrous cycle of female mice is similar to that of humans, although the estrous cycle of mice is shorter than that of humans[55].

In this study, we initially established a mouse POF model by administration of Cy and Bu as the most effective chemotherapeutic drugs. The results indicated that Cy plus Bu in our established model (POF2) significantly decreased the number of follicles at various stages of development and significantly decreased ovarian size and body weight. In line with previous studies, chemotherapy increased primordial follicle recruitment, which led to significant decreases in the number of follicles at different developmental stages[35,56]. Apoptotic cells significantly increased in our established POF model, which was consistent with previous findings where chemotherapeutic drugs destroyed highly proliferating cells by activation of apoptosis[57]. We observed increased FSH levels and decreased E2 levels, which supported results of studies that showed similar patterns of hormonal changes in POF[15]. Previous studies demonstrated that chemotherapeutic drugs can cause POF in various species such as mouse, rat, rabbit and human[16,58-61]. Our results were consistent with previous reports as we showed a decrease in the number of follicles, decreased serum E2 levels, increased serum FSH levels and infertility.

MSCs features depend on both the tissue source from which they were obtained and the species. Previous studies indicated that MSCs obtained from various species and sources differ in their biological characteristics such as surface marker expression, proliferative capacity, multilineage differentiation potential and immunomodulation feature[62,63]. In this study, we investigated biological properties of ES-MSCs and BM-MSCs. We have found that ES-MSCs and BM-MSCs both expressed homing cell adhesion molecule, CD73, CD90 and endoglin, but they showed no expression of CD34, protein tyrosine phosphatase receptor type C and CD 11b, which is consistent with a previous study[31]. We indicated that ES-MSCs showed enhanced proliferation capacity compared to the BM-MSCs. On the fourth and fifth passages, there were significant differences between ES-MSCs and BM-MSCs. Previous studies have similarly reported that ES-MSCs are more proliferative compared to BM-MSCs[31,33].

In addition, we demonstrated that multilineage differentiation potential of BM-MSCs was greater than ES-MSCs. This finding was consistent with previous studies[31,33]. MSCs from different species and sources produce different cytokines. Our results were consistent with previous studies that cytokines secreted from MSCs could influence cell proliferation, differentiation, survival and tissue repair[64,65]. We observed no significant difference between ES-MSCs and BM-MSCs secreted cytokines in culture medium.

We transplanted human ES-MSCs into a mouse animal model and showed their capability in restoring ovarian function in POF. In support of transplantation of human derived MSCs to another species, previous studies have demonstrated that the transplantation of MSCs derived from various human tissues including menstrual blood, umbilical cord and amniotic fluid into animal models of POF restore ovarian function[66].

In this study, we transplanted ES-MSCs into a mouse model of POF to investigate the role of these cells and mechanisms of action for improvement of POF. Our results indicated that both ES-MSCs and BM-MSCs showed a similar trend for improvement of POF in this animal model. ES-MSCs improved ovarian structure and function in these mice as evidenced by the increased number of follicles, decreased granulosa cell apoptosis and restored FSH and E2 to near normal levels. E2 is mainly secreted by granulosa cells, which inhibit FSH secretion. Increased FSH levels could accelerate recruitment of follicles and deplete the follicular pool[14,67,68]. Increased apoptosis in the POF group might result in deceased E2 and FSH levels. Transplantation of ES-MSCs inhibited granulosa cell apoptosis and increased E2 secretion, which led to decreases in FSH; therefore, the decreased level of FSH in the ES-MSCs transplantation group resulted in an increased number of follicles.

Gene expression and Western blot results reinforced our hypothesis. There were significant increases in *Amh* expression (granulosa cell marker) and no difference in *Gdf9* expression (oocyte marker). Expression of *Bcl2* was upregulated in both of the MSC transplantation groups compared with the POF group, whereas *caspase 3* expression was downregulated in both of these groups compared with the POF group.

Immunohistochemistry results agreed with the real-time PCR results and indicated that MSCs could increase Amh expression compared with the POF mouse group. Folliculogenesis is mainly affected by interactions between the oocyte and granulosa cells[69]. Amh is expressed by granulosa cells and plays an important role in follicle growth[70,71]. We observed decreased apoptosis of granulosa cells after transplantation of the MSCs; therefore, ES-MSCs maintained the follicular niche by inhibiting apoptosis of granulosa cells. Previous findings of granulosa cell function in supporting oocytes also confirmed our results[72]. Therefore, granulosa cells support oocytes during development from the primordial state to maturation.

We observed that the ES-MSCs secreted VEGF, IGF-2 and HGF *in vitro*. VEGF, IGF-2 and HGF have an important role in inhibiting granulosa cell apoptosis, stimulating granulosa cell proliferation, inducing angiogenesis and follicle growth. VEGF promotes granulosa and endothelial cell proliferation. IGF-2 and HGF play an important role in suppressing apoptosis of granulosa cells that promote follicle maturation[73-77]. We observed decreased mRNA and protein expression of caspase 3 in both of the MSC transplantation groups compared with the POF group. The caspase family members are important regulators of apoptosis. Caspase 3 is an effector caspase; its activation results in the final phase of cellular death[78]. Our study results suggested that ES-MSCs may have decreased caspase 3 expression in the ES-MSC transplantation group by releasing VEGF, HGF and IGF-2; therefore, these cytokines may inhibit apoptosis in granulosa cells by upregulation of *Bcl2* and downregulation of *caspase 3* in the ovaries of POF mice. Therefore, there was increased expression of the granulosa cell marker (Amh) after transplantation of the ES-MSCs. Our results might indicate that cytokines secreted by ES-MSCs reduce granulosa cell apoptosis and increase follicles by increasing E2 secretion.

We observed no significant difference in *Gdf9* expressionin both MSC transplantation groups compared with POF. Gdf9 is an adult oocyte-specific marker[79,80], and this finding might indicate that transplantation of ES-MSCs restored ovarian function in POF mice *via* an indirect effect due to cytokine secretion rather than direct differentiation to oocytes.

These findings suggested that a possible mechanism by ES-MSCs and BM-MSCs restored the injured ovary by cytokine suppression of granulosa cell apoptosis and increased follicular growth. In line with our findings, the results from previous studies suggest that MSCs have an effect on restoring ovarian function by the paracrine mechanism of cytokines[81-85], which plays an important role in increased granulosa cell resistance to chemotherapeutic drugs and improves the ovarian microenvironment and follicle growth[58].

In conclusion, our results indicated that human ES-MSCs could restore ovarian structure and function in chemotherapy-induced POF mice and improve fertility. Transplantation of ES-MSCs improved the disturbed endocrine secretion system, reduced apoptosis rate in the ovaries, and improved folliculogenesis possibly through a paracrine effect and ovarian cell survival. Therefore, ES-MSCs could be a promising source for stem cell therapy in individuals with POF.

**ARTICLE HIGHLIGHTS**

***Research background***

Premature ovarian failure (POF) is characterized by amenorrhea, hypoestrogenemia, high gonadotropins and infertility in women under 40-years-old. Previous reports demonstrated that various tissue-specific stem cells could restore ovarian function and folliculogenesis in chemotherapy-induced POF mice.

***Research motivation***

Human embryonic stem cell-derived MSC (ES-MSC) have advantages, such as higher proliferation, more potent anti-inflammatory properties and lack of obstacles of harvesting tissue-specific MSCs that make them attractive candidates for restoring fertility in patients with POF.

***Research objectives***

The aim of this study was to evaluate the therapeutic efficacy of ES-MSCs in a model of chemotherapy-induced POF.

***Research methods***

In this study, we initially established a mouse POF model by administration of cyclophosphamide and busulfan, then we transplanted ES-MSCs and bone marrow-derived MSC (BM-MSC) into a mouse model of POF to investigate the role of these cells and mechanisms of action for improvement of POF.

***Research results***

The POF model established by the 100 mg/kg dose of cyclophosphamide showed significant decreases in body weight, follicle count and estradiol level but had an increased follicle-stimulating hormone level. ES-MSC and/or BM-MSC transplantation significantly improved body weight, follicle count, hormone secretion, survival rate and reproductive function in POF mice. Gene expression and Western blot analysis, terminal deoxynucleotidyl transferase mediated 2-deoxyuridine 5-triphosphate nick end labelling assay and immunohistochemistry indicated that the ES-MSCs or BM-MSCs reduced apoptosis in the follicles and restored fertility in chemotherapy-induced POF mice. The results of this study indicated that the effects of ES-MSCs and BM-MSCs in restoring ovarian function appear *via* the paracrine mechanisms of cytokines.

***Research conclusions***

Our findings demonstrated that human ES-MSCs, similar to BM-MSCs, improved ovarian function and restored fertility in a mouse POF model.

***Research perspectives***

Our present study results suggest that human ES-MSCs could be a promising source for stem cell therapy in individuals with POF.

**REFERENCES**

1 **Maclaran K**, Panay N. Premature ovarian failure. *J Fam Plann Reprod Health Care* 2011; **37**: 35-42 [PMID: 21367702 DOI: 10.1136/jfprhc.2010.0015]

2 **Woad KJ**, Watkins WJ, Prendergast D, Shelling AN. The genetic basis of premature ovarian failure. *Aust N Z J Obstet Gynaecol* 2006; **46**: 242-244 [PMID: 16704481 DOI: 10.1111/j.1479-828X.2006.00585.x]

3 **Stearns V**, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. *Nat Rev Cancer* 2006; **6**: 886-893 [PMID: 17036039 DOI: 10.1038/nrc1992]

4 **Manger K**, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. *Autoimmun Rev* 2006; **5**: 269-272 [PMID: 16697968 DOI: 10.1016/j.autrev.2005.10.001]

5 **Laven JS**. Primary Ovarian Insufficiency. *Semin Reprod Med* 2016; **34**: 230-234 [PMID: 27513024 DOI: 10.1055/s-0036-1585402]

6 Fenton AJ. Premature ovarian insufficiency: Pathogenesis and management. J Midlife Health 2015; 6: 147-153 [PMID: 26903753 DOI: 10.4103/0976-7800.172292]

7 **Santoro N**. Mechanisms of premature ovarian failure. *Ann Endocrinol (Paris)* 2003; **64**: 87-92 [PMID: 12773939 DOI: AE-04-2003-64-2-0003-4266-101019-ART06]

8 **Stroud JS**, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. *Fertil Steril* 2009; **92**: 417-427 [PMID: 18774559 DOI: 10.1016/j.fertnstert.2008.07.1714]

9 **Salama M**, Winkler K, Murach KF, Seeber B, Ziehr SC, Wildt L. Female fertility loss and preservation: threats and opportunities. *Ann Oncol* 2013; **24**: 598-608 [PMID: 23129121 DOI: 10.1093/annonc/mds514]

10 **Liu T**, Huang Y, Zhang J, Qin W, Chi H, Chen J, Yu Z, Chen C. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. *Stem Cells Dev* 2014; **23**: 1548-1557 [PMID: 24593672 DOI: 10.1089/scd.2013.0371]

11 **Song D**, Zhong Y, Qian C, Zou Q, Ou J, Shi Y, Gao L, Wang G, Liu Z, Li H, Ding H, Wu H, Wang F, Wang J, Li H. Human Umbilical Cord Mesenchymal Stem Cells Therapy in Cyclophosphamide-Induced Premature Ovarian Failure Rat Model. *Biomed Res Int* 2016; **2016**: 2517514 [PMID: 27047962 DOI: 10.1155/2016/2517514]

12 **Su J**, Ding L, Cheng J, Yang J, Li X, Yan G, Sun H, Dai J, Hu Y. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency. *Hum Reprod* 2016; **31**: 1075-1086 [PMID: 26965432 DOI: 10.1093/humrep/dew041]

13 **Lai D**, Wang F, Yao X, Zhang Q, Wu X, Xiang C. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. *J Transl Med* 2015; **13**: 155 [PMID: 25964118 DOI: 10.1186/s12967-015-0516-y]

14 **Liu R**, Zhang X, Fan Z, Wang Y, Yao G, Wan X, Liu Z, Yang B, Yu L. Human amniotic mesenchymal stem cells improve the follicular microenvironment to recover ovarian function in premature ovarian failure mice. *Stem Cell Res Ther* 2019; **10**: 299 [PMID: 31578152 DOI: 10.1186/s13287-019-1315-9]

15 **Chen L**, Guo S, Wei C, Li H, Wang H, Xu Y. Effect of stem cell transplantation of premature ovarian failure in animal models and patients: A meta-analysis and case report. *Exp Ther Med* 2018; **15**: 4105-4118 [PMID: 29755593 DOI: 10.3892/etm.2018.5970]

16 **Edessy M**, Hosni HN, Shady Y, Waf Y, Bakr S, Kamel M. Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. *Acta Med Int* 2016; **3**: 19-23 [DOI: 10.5530/ami.2016.1.7]

17 **Lotfinia M**, Kadivar M, Piryaei A, Pournasr B, Sardari S, Sodeifi N, Sayahpour FA, Baharvand H. Effect of Secreted Molecules of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells on Acute Hepatic Failure Model. *Stem Cells Dev* 2016; **25**: 1898-1908 [PMID: 27676103 DOI: 10.1089/scd.2016.0244]

18 **Bak XY**, Lam DH, Yang J, Ye K, Wei EL, Lim SK, Wang S. Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma. *Hum Gene Ther* 2011; **22**: 1365-1377 [PMID: 21425958 DOI: 10.1089/hum.2010.212]

19 **Le Blanc K**, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. *J Intern Med* 2007; **262**: 509-525 [PMID: 17949362 DOI: 10.1111/j.1365-2796.2007.01844.x]

20 **Aggarwal S**, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; **105**: 1815-1822 [PMID: 15494428 DOI: 10.1182/blood-2004-04-1559]

21 **Jiang XX**, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood* 2005; **105**: 4120-4126 [PMID: 15692068 DOI: 10.1182/blood-2004-02-0586]

22 **Beyth S**, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* 2005; **105**: 2214-2219 [PMID: 15514012 DOI: 10.1182/blood-2004-07-2921]

23 **Ren G**, Su J, Zhang L, Zhao X, Ling W, L'huillie A, Zhang J, Lu Y, Roberts AI, Ji W, Zhang H, Rabson AB, Shi Y. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. *Stem Cells* 2009; **27**: 1954-1962 [PMID: 19544427 DOI: 10.1002/stem.118]

24 **Wynn RF**, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. *Blood* 2004; **104**: 2643-2645 [PMID: 15251986 DOI: 10.1182/blood-2004-02-0526]

25 **Ip JE**, Wu Y, Huang J, Zhang L, Pratt RE, Dzau VJ. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. *Mol Biol Cell* 2007; **18**: 2873-2882 [PMID: 17507648 DOI: 10.1091/mbc.e07-02-0166]

26 **Nahar S**, Nakashima Y, Miyagi-Shiohira C, Kinjo T, Kobayashi N, Saitoh I, Watanabe M, Noguchi H, Fujita J. A Comparison of Proteins Expressed between Human and Mouse Adipose-Derived Mesenchymal Stem Cells by a Proteome Analysis through Liquid Chromatography with Tandem Mass Spectrometry. *Int J Mol Sci* 2018; **19**: [PMID: 30404232 DOI: 10.3390/ijms19113497]

27 **Gadkari R**, Zhao L, Teklemariam T, Hantash BM. Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy. *Regen Med* 2014; **9**: 453-465 [PMID: 25159063 DOI: 10.2217/rme.14.13]

28 **Wang Q**, Yang Q, Wang Z, Tong H, Ma L, Zhang Y, Shan F, Meng Y, Yuan Z. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy. *Hum Vaccin Immunother* 2016; **12**: 85-96 [PMID: 26186552 DOI: 10.1080/21645515.2015.1030549]

29 **Karlsson C**, Emanuelsson K, Wessberg F, Kajic K, Axell MZ, Eriksson PS, Lindahl A, Hyllner J, Strehl R. Human embryonic stem cell-derived mesenchymal progenitors--potential in regenerative medicine. *Stem Cell Res* 2009; **3**: 39-50 [PMID: 19515621 DOI: 10.1016/j.scr.2009.05.002]

30 **Mardpour S**, Hassani SN, Mardpour S, Sayahpour F, Vosough M, Ai J, Aghdami N, Hamidieh AA, Baharvand H. Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury. *J Cell Physiol* 2018; **233**: 9330-9344 [PMID: 29266258 DOI: 10.1002/jcp.26413]

31 **Brown PT**, Squire MW, Li WJ. Characterization and evaluation of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. *Cell Tissue Res* 2014; **358**: 149-164 [PMID: 24927918 DOI: 10.1007/s00441-014-1926-5]

32 **Fu X**, Chen Y, Xie FN, Dong P, Liu WB, Cao Y, Zhang WJ, Xiao R. Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. *Tissue Eng Part A* 2015; **21**: 616-626 [PMID: 25256849 DOI: 10.1089/ten.TEA.2013.0651]

33 **Krylova TA**, Kol'tsova AM, Zenin VV, Musorina AS, Iakovleva TK, Polianskaia GG. [Comparative characteristics of new mesenchymal stem cell lines derived from human embryonic stem cells, bone marrow and foreskin]. *Tsitologiia* 2012; **54**: 5-16 [PMID: 22567895]

34 **Wang X**, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, Kouris NA, Yavanian GJ, Lu SJ, Pachter JS, Crocker SJ, Lanza R, Xu RH. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. *Stem Cell Reports* 2014; **3**: 115-130 [PMID: 25068126 DOI: 10.1016/j.stemcr.2014.04.020]

35 **Rosendahl M**, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. *Fertil Steril* 2010; **94**: 156-166 [PMID: 19342041 DOI: 10.1016/j.fertnstert.2009.02.043]

36 **Mohamed SA**, Shalaby SM, Abdelaziz M, Brakta S, Hill WD, Ismail N, Al-Hendy A. Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure. *Reprod Sci* 2018; **25**: 51-63 [PMID: 28460567 DOI: 10.1177/1933719117699705]

37 **Xiao GY**, Liu IH, Cheng CC, Chang CC, Lee YH, Cheng WT, Wu SC. Amniotic fluid stem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy. *PLoS One* 2014; **9**: e106538 [PMID: 25198549 DOI: 10.1371/journal.pone.0106538]

38 **Luo Q**, Yin N, Zhang L, Yuan W, Zhao W, Luan X, Zhang H. Role of SDF-1/CXCR4 and cytokines in the development of ovary injury in chemotherapy drug induced premature ovarian failure mice. *Life Sci* 2017; **179**: 103-109 [PMID: 28478265 DOI: 10.1016/j.lfs.2017.05.001]

39 **Lai D**, Wang F, Dong Z, Zhang Q. Skin-derived mesenchymal stem cells help restore function to ovaries in a premature ovarian failure mouse model. *PLoS One* 2014; **9**: e98749 [PMID: 24879098 DOI: 10.1371/journal.pone.0098749]

40 **Zhang Q**, Xu M, Yao X, Li T, Wang Q, Lai D. Human amniotic epithelial cells inhibit granulosa cell apoptosis induced by chemotherapy and restore the fertility. *Stem Cell Res Ther* 2015; **6**: 152 [PMID: 26303743 DOI: 10.1186/s13287-015-0148-4]

41 **Lai D**, Wang F, Chen Y, Wang L, Wang Y, Cheng W. Human amniotic fluid stem cells have a potential to recover ovarian function in mice with chemotherapy-induced sterility. *BMC Dev Biol* 2013; **13**: 34 [PMID: 24006896 DOI: 10.1186/1471-213X-13-34]

42 **Sun M**, Wang S, Li Y, Yu L, Gu F, Wang C, Yao Y. Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. *Stem Cell Res Ther* 2013; **4**: 80 [PMID: 23838374 DOI: 10.1186/scrt231]

43 **Liu T**, Huang Y, Guo L, Cheng W, Zou G. CD44+/CD105+ human amniotic fluid mesenchymal stem cells survive and proliferate in the ovary long-term in a mouse model of chemotherapy-induced premature ovarian failure. *Int J Med Sci* 2012; **9**: 592-602 [PMID: 23028242 DOI: 10.7150/ijms.4841]

44 **Pascuali N**, Scotti L, Di Pietro M, Oubiña G, Bas D, May M, Gómez Muñoz A, Cuasnicú PS, Cohen DJ, Tesone M, Abramovich D, Parborell F. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure. *Hum Reprod* 2018; **33**: 844-859 [PMID: 29534229 DOI: 10.1093/humrep/dey045]

45 **Tilly JL**. Ovarian follicle counts--not as simple as 1, 2, 3. *Reprod Biol Endocrinol* 2003; **1**: 11 [PMID: 12646064 DOI: 10.1186/1477-7827-1-11]

46 **Neishabouri SH**, Hutson SM, Davoodi J. Chronic activation of mTOR complex 1 by branched chain amino acids and organ hypertrophy. *Amino Acids* 2015; **47**: 1167-1182 [PMID: 25721400 DOI: 10.1007/s00726-015-1944-y]

47 **Jänicke RU**, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *J Biol Chem* 1998; **273**: 9357-9360 [PMID: 9545256 DOI: 10.1074/jbc.273.16.9357]

48 **Yacobi K**, Wojtowicz A, Tsafriri A, Gross A. Gonadotropins enhance caspase-3 and -7 activity and apoptosis in the theca-interstitial cells of rat preovulatory follicles in culture. *Endocrinology* 2004; **145**: 1943-1951 [PMID: 14726442 DOI: 10.1210/en.2003-1395]

49 **Kupcova Skalnikova H**. Proteomic techniques for characterisation of mesenchymal stem cell secretome. *Biochimie* 2013; **95**: 2196-2211 [PMID: 23880644 DOI: 10.1016/j.biochi.2013.07.015]

50 **Squillaro T**, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update. *Cell Transplant* 2016; **25**: 829-848 [PMID: 26423725 DOI: 10.3727/096368915X689622]

51 **He Y**, Chen D, Yang L, Hou Q, Ma H, Xu X. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. *Stem Cell Res Ther* 2018; **9**: 263 [PMID: 30286808 DOI: 10.1186/s13287-018-1008-9]

52 **Fu Y**, Karbaat L, Wu L, Leijten J, Both SK, Karperien M. Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration. *Tissue Eng Part B Rev* 2017; **23**: 515-528 [PMID: 28490258 DOI: 10.1089/ten.TEB.2016.0365]

53 **Kusuma GD**, Carthew J, Lim R, Frith JE. Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. *Stem Cells Dev* 2017; **26**: 617-631 [PMID: 28186467 DOI: 10.1089/scd.2016.0349]

54 **Torrealday S**, Kodaman P, Pal L. Premature Ovarian Insufficiency - an update on recent advances in understanding and management. *F1000Res* 2017; **6**: 2069 [PMID: 29225794 DOI: 10.12688/f1000research.11948.1]

55 **Zhang J**, Fang L, Shi L, Lai Z, Lu Z, Xiong J, Wu M, Luo A, Wang S. Protective effects and mechanisms investigation of Kuntai capsule on the ovarian function of a novel model with accelerated aging ovaries. *J Ethnopharmacol* 2017; **195**: 173-181 [PMID: 27845267 DOI: 10.1016/j.jep.2016.11.014]

56 **Goswami D**, Conway GS. Premature ovarian failure. *Hum Reprod Update* 2005; **11**: 391-410 [PMID: 15919682 DOI: 10.1093/humupd/dmi012]

57 **Zhao XJ**, Huang YH, Yu YC, Xin XY. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. *Gynecol Oncol* 2010; **118**: 69-75 [PMID: 20417958 DOI: 10.1016/j.ygyno.2010.03.021]

58 **Fu X**, He Y, Xie C, Liu W. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage. *Cytotherapy* 2008; **10**: 353-363 [PMID: 18574768 DOI: 10.1080/14653240802035926]

59 **Abd-Allah SH**, Shalaby SM, Pasha HF, El-Shal AS, Raafat N, Shabrawy SM, Awad HA, Amer MG, Gharib MA, El Gendy EA, Raslan AA, El-Kelawy HM. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. *Cytotherapy* 2013; **15**: 64-75 [PMID: 23260087 DOI: 10.1016/j.jcyt.2012.08.001]

60 **Fleischer RT**, Vollenhoven BJ, Weston GC. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. *Obstet Gynecol Surv* 2011; **66**: 248-254 [PMID: 21756407 DOI: 10.1097/OGX.0b013e318224e97b]

61 **Zhang T**, Yan D, Yang Y, Ma A, Li L, Wang Z, Pan Q, Sun Z. The comparison of animal models for premature ovarian failure established by several different source of inducers. *Regul Toxicol Pharmacol* 2016; **81**: 223-232 [PMID: 27612992 DOI: 10.1016/j.yrtph.2016.09.002]

62 **Uder C**, Brückner S, Winkler S, Tautenhahn HM, Christ B. Mammalian MSC from selected species: Features and applications. *Cytometry A* 2018; **93**: 32-49 [PMID: 28906582 DOI: 10.1002/cyto.a.23239]

63 **Kozlowska U**, Krawczenko A, Futoma K, Jurek T, Rorat M, Patrzalek D, Klimczak A. Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues. *World J Stem Cells* 2019; **11**: 347-374 [PMID: 31293717 DOI: 10.4252/wjsc.v11.i6.347]

64 **Majumdar MK**, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. *J Hematother Stem Cell Res* 2000; **9**: 841-848 [PMID: 11177595 DOI: 10.1089/152581600750062264]

65 **Guan YT**, Xie Y, Li DS, Zhu YY, Zhang XL, Feng YL, Chen YP, Xu LJ, Liao PF, Wang G. Comparison of biological characteristics of mesenchymal stem cells derived from the human umbilical cord and decidua parietalis. *Mol Med Rep* 2019; **20**: 633-639 [PMID: 31180542 DOI: 10.3892/mmr.2019.10286]

66 **Yoon SY**. Mesenchymal stem cells for restoration of ovarian function. *Clin Exp Reprod Med* 2019; **46**: 1-7 [PMID: 30827071 DOI: 10.5653/cerm.2019.46.1.1]

67 **Dewailly D**, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. *Hum Reprod Update* 2016; **22**: 709-724 [PMID: 27566840 DOI: 10.1093/humupd/dmw027]

68 **Busch AS**, Hagen CP, Almstrup K, Main KM, Juul A. Genetic variations altering FSH action affect circulating hormone levels as well as follicle growth in healthy peripubertal girls. *Hum Reprod* 2016; **31**: 897-904 [PMID: 26905078 DOI: 10.1093/humrep/dew022]

69 **Cecconi S**, Ciccarelli C, Barberi M, Macchiarelli G, Canipari R. Granulosa cell-oocyte interactions. *Eur J Obstet Gynecol Reprod Biol* 2004; **115** Suppl 1: S19-S22 [PMID: 15196711 DOI: 10.1016/j.ejogrb.2004.01.010]

70 **Kevenaar ME**, Meerasahib MF, Kramer P, van de Lang-Born BM, de Jong FH, Groome NP, Themmen AP, Visser JA. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. *Endocrinology* 2006; **147**: 3228-3234 [PMID: 16556768 DOI: 10.1210/en.2005-1588]

71 **La Marca A**, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? *Clin Endocrinol (Oxf)* 2006; **64**: 603-610 [PMID: 16712660 DOI: 10.1111/j.1365-2265.2006.02533.x]

72 **Matzuk MM**, Burns KH, Viveiros MM, Eppig JJ. Intercellular communication in the mammalian ovary: oocytes carry the conversation. *Science* 2002; **296**: 2178-2180 [PMID: 12077402 DOI: 10.1126/science.1071965]

73 **Kosaka N**, Sudo N, Miyamoto A, Shimizu T. Vascular endothelial growth factor (VEGF) suppresses ovarian granulosa cell apoptosis in vitro. *Biochem Biophys Res Commun* 2007; **363**: 733-737 [PMID: 17904528 DOI: 10.1016/j.bbrc.2007.09.061]

74 **Quintana R**, Kopcow L, Marconi G, Sueldo C, Speranza G, Barañao RI. Relationship of ovarian stimulation response with vascular endothelial growth factor and degree of granulosa cell apoptosis. *Hum Reprod* 2001; **16**: 1814-1818 [PMID: 11527881 DOI: 10.1093/humrep/16.9.1814]

75 **Uzumcu M**, Pan Z, Chu Y, Kuhn PE, Zachow R. Immunolocalization of the hepatocyte growth factor (HGF) system in the rat ovary and the anti-apoptotic effect of HGF in rat ovarian granulosa cells in vitro. *Reproduction* 2006; **132**: 291-299 [PMID: 16885537 DOI: 10.1530/rep.1.00989]

76 **Zachow R**, Uzumcu M. The hepatocyte growth factor system as a regulator of female and male gonadal function. *J Endocrinol* 2007; **195**: 359-371 [PMID: 18000299 DOI: 10.1677/JOE-07-0466]

77 **Martinez-Chequer JC**, Stouffer RL, Hazzard TM, Patton PE, Molskness TA. Insulin-like growth factors-1 and -2, but not hypoxia, synergize with gonadotropin hormone to promote vascular endothelial growth factor-A secretion by monkey granulosa cells from preovulatory follicles. *Biol Reprod* 2003; **68**: 1112-1118 [PMID: 12606472 DOI: 10.1095/biolreprod.102.011155]

78 **Nicholson DW**. Caspase structure, proteolytic substrates, and function during apoptotic cell death. *Cell Death Differ* 1999; **6**: 1028-1042 [PMID: 10578171 DOI: 10.1038/sj.cdd.4400598]

79 **Hayashi M**, McGee EA, Min G, Klein C, Rose UM, van Duin M, Hsueh AJ. Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. *Endocrinology* 1999; **140**: 1236-1244 [PMID: 10067849 DOI: 10.1210/endo.140.3.6548]

80 **Gupta SK**, Jethanandani P, Afzalpurkar A, Kaul R, Santhanam R. Prospects of zona pellucida glycoproteins as immunogens for contraceptive vaccine. *Hum Reprod Update* 1997; **3**: 311-324 [PMID: 9459277 DOI: 10.1093/humupd/3.4.311]

81 **Wang Z**, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. *Stem Cell Res Ther* 2017; **8**: 11 [PMID: 28114977 DOI: 10.1186/s13287-016-0458-1]

82 **Liu J**, Zhang H, Zhang Y, Li N, Wen Y, Cao F, Ai H, Xue X. Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats. *Mol Cells* 2014; **37**: 865-872 [PMID: 25410907 DOI: 10.14348/molcells.2014.0145]

83 **Yao X**, Guo Y, Wang Q, Xu M, Zhang Q, Li T, Lai D. The Paracrine Effect of Transplanted Human Amniotic Epithelial Cells on Ovarian Function Improvement in a Mouse Model of Chemotherapy-Induced Primary Ovarian Insufficiency. *Stem Cells Int* 2016; **2016**: 4148923 [PMID: 26664408 DOI: 10.1155/2016/4148923]

84 **Takehara Y**, Yabuuchi A, Ezoe K, Kuroda T, Yamadera R, Sano C, Murata N, Aida T, Nakama K, Aono F, Aoyama N, Kato K, Kato O. The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function. *Lab Invest* 2013; **93**: 181-193 [PMID: 23212100 DOI: 10.1038/labinvest.2012.167]

85 **Zhang Q**, Bu S, Sun J, Xu M, Yao X, He K, Lai D. Paracrine effects of human amniotic epithelial cells protect against chemotherapy-induced ovarian damage. *Stem Cell Res Ther* 2017; **8**: 270 [PMID: 29179771 DOI: 10.1186/s13287-017-0721-0]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Institutional Review Board at Royan Institute.

**Institutional animal care and use committee statement:** All animal experiments of the study were reviewed and approved by the Institutional Ethical Committee at Royan Institute.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared according to these guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** International society of Cell Therapy; International Society for Stem Cell Research; and the World Academy of Science.

**Peer-review started:** February 22, 2020

**First decision:** April 29, 2020

**Article in press:** July 18, 2020

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** Iran

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0


Grade B (Very good): 0

Grade C (Good): C


Grade D (Fair): 0

Grade E (Poor): 0


**P-Reviewer:** Tanabe S **S-Editor:** Gong ZM **L-Editor:** Filipodia **P-Editor:** Wang LL




**Figure 1 Derivation and identification of human embryonic stem cell-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells.** A: Schematic presentation of the procedure used to derive human mesenchymal stem cells (MSCs) from embryonic stem (ES) cells. Colonies of ES cells were enzymatically detached and cultured for 10 d in suspension to form embryoid bodies, which were then plated onto gelatin-coated tissue culture plates. After 10 d, outgrowths of the cells that sprouted from embryoid bodies were mechanically isolated by a cell scraper and subsequently expanded in mesenchymal stem cell culture medium; B and C: Morphology and karyotype of ES-MSCs and BM-MSCs. Passage-5 ES-MSCs and BM-MSCs showed a fibroblastic morphology and normal karyotype; D: Alizarin red staining after 14 d of culture in osteogenic medium indicated the osteogenic differentiation potential of ES-MSCs and BM-MSCs (P4). Oil red staining after 21 d of culture in adipogenic medium showed the adipogenic differentiation potential of ES-MSCs and BM-MSCs (P4). Alcian blue staining after 21 d of culture in chondrogenic medium showed chondrogenic differentiation potential of ES-MSCs and BM-MSCs; E, F: Flow cytometric analysis indicated that cultured ES-MSCs and BM-MSCs expressed CD44, CD90, CD73 and endoglin (CD105), but not hematopoietic lineage markers CD11b, CD34 and protein tyrosine phosphatase receptor type C (CD45); G: ES-MSCs proliferated more rapidly than BM-MSCs. Results are expressed as mean ± standard error, a*P* < 0.05, b*P* < 0.01; *n* = 3-5. ES-MSCs: Embryonic stem cell-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; EBs: Embryoid bodies; bFGF: basic fibroblast growth factor; P: Passage.




**Figure 2 Establishment of a mouse model of premature ovarian failure.** A:premature ovarian failure (POF) groups were treated with different dosages of cyclophosphamide and busulfan; B: Body weight changes in the intact and POF groups after 10 d showed that the POF1 and POF2 groups had significant decreases in body weights; C: Ovarian pathology of the intact and POF groups 10 d after injection of cyclophosphamide and busulfan . Follicle count revealed that there were fewer normal follicles in the POF groups than in the intact mice. The ovaries of the intact group contained large numbers of follicles at all developmental stages, whereas the atrophic ovaries of the POF groups had fewer follicles at each stage; D, E: Serum levels of follicle stimulating hormone and estradiol 10 d after injection of cyclophosphamide and busulfan. Serum levels of follicle stimulating hormone were significantly increased in the POF1 and POF2 groups compared to those of the intact group. Serum levels of estradiol were significantly decreased in the POF1 and POF2 groups compared with the intact group; F: Apoptosis rate in the ovary. Green fluorescence indicated the presence of apoptotic cells in the POF1, POF2, POF3 and POF4 groups; G: Survival rate in the POF groups after 10 d. The survival percent showed a significant decrease in the POF1 group compared with the POF2 group. All data are presented as mean ± standard error. Small letters (a) indicate the significance (*P* < 0.05) compared to groups labeled by similar capital letters (A); a*P* < 0.05 significance of experimental groups *vs* the intact group; *n* = 3-5. POF: Premature ovarian failure; Cy: Cyclophosphamide; Bu: Busulfan; FSH: Follicle stimulating hormone; E2: Estradiol.



**Figure 3 Effects of human embryonic stem cell-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells transplantation in mice with premature ovarian failure.** A: Transplantation of embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) and/or bone marrow-derived mesenchymal stem cells (BM-MSCs) improved body weights in mice with premature ovarian failure after 4 wk; B: Survival rate 4 wk after ES-MSCs and/or BM-MSCs transplantation. Survival rate significantly increased in both the ES-MSCs and/or BM-MSCs transplanted mice (more than 60%) compared with the vehicle group (20%); C: The follicle number increased after transplantation. The number of follicles at all stages of development in both cell transplanted groups was significantly higher than that of the vehicle mice, while it was lower than the intact mice; D, E: Both cell transplantations rescued hormone secretion in premature ovarian failure mice**.** Serum follicle stimulating hormone levels decreased significantly in both cell transplanted groups compared to the vehicle group. The serum estradiol level significantly recovered after both cell transplantations compared to the vehicle group. All data are presented as mean ± standard error. Small letters (a, c) indicate the significance (*P* < 0.05) compared to groups labeled by similar capital letters (A, C); a*P* < 0.05 significance of experimental groups *vs* the intact group; c*P* < 0.05 significance of ES-MSC and BM-MSC groups *vs* the vehicle group; *n*= 3-5. ES-MSCs: Embryonic stem cell-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; POF: Premature ovarian failure; FSH: Follicle stimulating hormone; E2: Estradiol.



**Figure 4 Human embryonic stem cell-derived mesenchymal stem cells and/or bone marrow-derived mesenchymal stem cells transplantation improved premature ovarian failure conditions.** A and B: Apoptosis was reduced after both cell transplantations. The green stain color indicates terminal deoxynucleotidyl transferase mediated 2-deoxyuridine 5-triphosphate nick end labelling-positive cells. Data at 4 wk showed decreased levels of apoptosis following transplantation of embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) and/or bone marrow-derived mesenchymal stem cells (BM-MSCs); C:Gene expression analysis showed that the expressions of B-cell lymphoma 2, vascular endothelial growth factor, insulin-like growth factor 2, anti-Müllerian hormone and growth/differentiation factor 9 significantly increased in both cell transplanted groups compared with the vehicle group, whereas cysteine-aspartic proteases 3 (*caspase 3)* significantly decreased in both cell transplanted groups compared to the vehicle group; D, E: Western blot analysis for cleaved-caspase 3 expression in the ovarian tissue. The results showed that cleaved-caspase 3 in ovarian tissue of the vehicle group significantly increased compared to the intact group. Cleaved-caspase 3 protein expression levels decreased in the ovaries from the ES-MSCs and BM-MSCs transplantation groups compared with the vehicle group; F: ELISA assessment of conditioned media of ES-MSCs and BM-MSCs for vascular endothelial growth factor, insulin-like growth factor 2 and hepatocyte growth factor. The results showed that ES-MSCs and BM-MSCs secreted vascular endothelial growth factor, insulin-like growth factor 2,and hepatocyte growth factor *in vitro*. All data are presented as mean ± standard error. Small letters (a, c) indicate the significance (*P* < 0.05) compared to groups labeled by similar capital letters (A, C), a*P* < 0.05, significance of experimental groups *vs* the intact group. c*P* < 0.05, significance of ES-MSC and BM-MSC groups *vs* the vehicle group. For figure 4C: a*P* < 0.05 significance of ES-MSC and BM-MSC groups *vs* the vehicle group, *n* = 3. ES-MSCs: Embryonic stem cell-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; POF: Premature ovarian failure; Bcl-2: B-cell lymphoma 2; Caspase 3: Cysteine-aspartic proteases 3; Vegf: Vascular endothelial growth factor; Igf-2: Insulin-like growth factor 2; Amh: Anti-Müllerian hormone; Gdf9: Growth/differentiation factor 9.



**Figure 5 Human embryonic stem cell-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells transplantation prevented follicular atresia and restored fertility in** **premature ovarian failure mice.** A: Immunohistochemical staining showed increased anti-Müllerian hormone expression in the ovaries from the embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) transplantation groups compared with the vehicle group; B, C: The percentage of pregnancies and the numbers of pups six weeks after both cell transplantations. The intact mice had a 100% (5 of 5) pregnancy rate, producing 32 live offspring. The embryonic stem cell-derived MSCs transplanted mice had a 60% (3 of 5) pregnancy rate, producing 16 live offspring. The bone marrow-derived MSCs transplanted mice had a 40% (2 of 5) pregnancy rate, producing nine live offspring. None of the premature ovarian failure mice became pregnant. Results are expressed as mean ± standard error, a*P* < 0.05, e*P* < 0.001, *n* = 3-5. ES-MSCs: Embryonic stem cell-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells.